Ontology highlight
ABSTRACT:
SUBMITTER: Hammam K
PROVIDER: S-EPMC5681654 | biostudies-literature | 2017 Nov
REPOSITORIES: biostudies-literature
Nature communications 20171110 1
Masitinib, a highly selective protein kinase inhibitor, can sensitise gemcitabine-refractory cancer cell lines when used in combination with gemcitabine. Here we report a reverse proteomic approach that identifies the target responsible for this sensitisation: the deoxycytidine kinase (dCK). Masitinib, as well as other protein kinase inhibitors, such as imatinib, interact with dCK and provoke an unforeseen conformational-dependent activation of this nucleoside kinase, modulating phosphorylation ...[more]